BR112021024020A2 - Ensaio de vetor viral de precisão ultra-alta - Google Patents

Ensaio de vetor viral de precisão ultra-alta

Info

Publication number
BR112021024020A2
BR112021024020A2 BR112021024020A BR112021024020A BR112021024020A2 BR 112021024020 A2 BR112021024020 A2 BR 112021024020A2 BR 112021024020 A BR112021024020 A BR 112021024020A BR 112021024020 A BR112021024020 A BR 112021024020A BR 112021024020 A2 BR112021024020 A2 BR 112021024020A2
Authority
BR
Brazil
Prior art keywords
viral vector
assay
cells
ultra
replication
Prior art date
Application number
BR112021024020A
Other languages
English (en)
Portuguese (pt)
Inventor
Hanna Peltonen
Jenni Mykkannen
Minna Hassinen
Nigel Parker
Seppo Yla-Herttuala
Original Assignee
Trizell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trizell Ltd filed Critical Trizell Ltd
Publication of BR112021024020A2 publication Critical patent/BR112021024020A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112021024020A 2019-05-30 2020-05-22 Ensaio de vetor viral de precisão ultra-alta BR112021024020A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/426,124 US12152281B2 (en) 2019-05-30 2019-05-30 Gene therapy vector contamination assay
PCT/US2020/034146 WO2020242913A1 (en) 2019-05-30 2020-05-22 Ultra-high-precision viral vector assay

Publications (1)

Publication Number Publication Date
BR112021024020A2 true BR112021024020A2 (pt) 2022-04-12

Family

ID=67984844

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024020A BR112021024020A2 (pt) 2019-05-30 2020-05-22 Ensaio de vetor viral de precisão ultra-alta

Country Status (10)

Country Link
US (2) US12152281B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976803A4 (cg-RX-API-DMAC7.html)
JP (2) JP7755490B2 (cg-RX-API-DMAC7.html)
KR (1) KR102999060B1 (cg-RX-API-DMAC7.html)
CN (1) CN113874514B (cg-RX-API-DMAC7.html)
AU (1) AU2020283526B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024020A2 (cg-RX-API-DMAC7.html)
CA (1) CA3140145A1 (cg-RX-API-DMAC7.html)
IL (1) IL288404B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020242913A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12152281B2 (en) 2019-05-30 2024-11-26 Trizell Ltd. Gene therapy vector contamination assay
CN111041131B (zh) * 2020-03-16 2020-07-10 广东永诺医疗科技有限公司 基于微滴式数字pcr的eb病毒检测试剂盒

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
WO2001044280A2 (en) 1999-12-14 2001-06-21 Genovo, Inc. Methods and compositions for the manufacture of replication incompetent adenovirus
EP1513956A2 (en) 2002-06-07 2005-03-16 Novartis AG Assay to detect replication competent viruses
WO2006060089A2 (en) 2004-10-25 2006-06-08 Biogen Idec Ma Inc. Novel methods for producing adenoviral vector preparations with reduced replication-competent adenovirus contamination and novel adenoviral vectors and preparations
WO2008079354A2 (en) 2006-12-22 2008-07-03 Schering Corporation Methods of detecting replication competent adenovirus
EP2553105B1 (en) 2010-04-01 2014-12-17 Weidong Xiao Compositions and methods for the production of recombinant virus vectors
CA2823193C (en) * 2010-12-27 2017-06-06 Ibis Biosciences, Inc. Quantitating high titer samples by digital pcr
CN102134613B (zh) * 2010-12-31 2013-01-30 中国人民解放军第三军医大学 重组慢病毒滴度的检测方法
DE102012100824A1 (de) * 2012-02-01 2013-09-05 Albert-Ludwigs-Universität Freiburg Gemultiplexte Digital PCR
WO2013163545A1 (en) * 2012-04-26 2013-10-31 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
EP3052644B1 (en) 2013-10-01 2019-07-10 Texcell Detection of rare microbiological nucleic acids
WO2015103367A1 (en) * 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
EP3387138B2 (en) 2015-12-11 2026-05-27 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
RS67367B1 (sr) * 2016-04-14 2025-11-28 Ferring Ventures Ltd Bioreaktor sa fiksiranim slojem sa pumpom/sistemom creva sa konstantnim protokom
GB2549799A (en) * 2016-04-29 2017-11-01 Nat Univ Ireland Galway A multiplex assay for the sensitive and specific detection and differentiation of Clostridium difficile
JP7483373B2 (ja) * 2016-07-29 2024-05-15 ジュノー セラピューティクス インコーポレイテッド 複製可能ウイルスの存在または非存在を評価するための方法
CN107794291A (zh) * 2017-04-10 2018-03-13 中山大学 一种抗新加坡石斑鱼虹彩病毒的药物筛选方法
CN108570449A (zh) * 2018-05-17 2018-09-25 石河子大学 一种带有自发性kshv裂解复制的神经元细胞的构建方法
US12152281B2 (en) 2019-05-30 2024-11-26 Trizell Ltd. Gene therapy vector contamination assay

Also Published As

Publication number Publication date
WO2020242913A1 (en) 2020-12-03
EP3976803A1 (en) 2022-04-06
CA3140145A1 (en) 2020-12-03
US20190292609A1 (en) 2019-09-26
IL288404B2 (en) 2025-03-01
JP2022534483A (ja) 2022-08-01
US20250163519A1 (en) 2025-05-22
IL288404B1 (en) 2024-11-01
US12152281B2 (en) 2024-11-26
KR20220016071A (ko) 2022-02-08
CN113874514A (zh) 2021-12-31
KR102999060B1 (ko) 2026-07-31
AU2020283526A1 (en) 2021-12-23
AU2020283526B2 (en) 2026-07-16
IL288404A (en) 2022-01-01
JP7755490B2 (ja) 2025-10-16
JP2025123368A (ja) 2025-08-22
EP3976803A4 (en) 2023-11-22
CN113874514B (zh) 2026-07-10

Similar Documents

Publication Publication Date Title
Gladue et al. Deletion of the A137R gene from the pandemic strain of African swine fever virus attenuates the strain and offers protection against the virulent pandemic virus
Anfasa et al. Phenotypic differences between Asian and African lineage Zika viruses in human neural progenitor cells
Lam et al. Unabated adenovirus replication following activation of the cGAS/STING-dependent antiviral response in human cells
Malouli et al. Cytomegaloviral determinants of CD8+ T cell programming and RhCMV/SIV vaccine efficacy
Pan et al. Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection
Fu et al. MicroRNA miR-21 attenuates human cytomegalovirus replication in neural cells by targeting Cdc25a
Wollebo et al. CRISPR/Cas9 system as an agent for eliminating polyomavirus JC infection
Hung et al. Regulation of autophagic activation by Rta of Epstein-Barr virus via the extracellular signal-regulated kinase pathway
Lurain et al. Human cytomegalovirus UL144 open reading frame: sequence hypervariability in low-passage clinical isolates
Botto et al. Human cytomegalovirus immediate early 86-kDa protein blocks transcription and induces degradation of the immature interleukin-1β protein during virion-mediated activation of the AIM2 inflammasome
Xie et al. Human cytomegalovirus exploits interferon-induced transmembrane proteins to facilitate morphogenesis of the virion assembly compartment
Pavlova et al. Disruption of gammaherpesvirus 68 gene 50 demonstrates that Rta is essential for virus replication
Krump et al. Merkel cell polyomavirus infection induces an antiviral innate immune response in human dermal fibroblasts
Baylis et al. Analysis of porcine circovirus type 1 detected in Rotarix vaccine
Ayllon et al. Strain-specific contribution of NS1-activated phosphoinositide 3-kinase signaling to influenza A virus replication and virulence
Vincent et al. Mechanism of protein kinase R inhibition by human cytomegalovirus pTRS1
Gallaher et al. A rapid Q-PCR titration protocol for adenovirus and helper-dependent adenovirus vectors that produces biologically relevant results
Oyaizu et al. Complementation of the function of glycoprotein H of human herpesvirus 6 variant A by glycoprotein H of variant B in the virus life cycle
Battivelli et al. Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5α, linking intrinsic and acquired immunity
Habison et al. Cross-species conservation of episome maintenance provides a basis for in vivo investigation of Kaposi's sarcoma herpesvirus LANA
Olson et al. Deletion of the vaccinia virus B1 kinase reveals essential functions of this enzyme complemented partly by the homologous cellular kinase VRK2
Ismail et al. Selection pressure in the human adenovirus fiber knob drives cell specificity in epidemic keratoconjunctivitis
Wang et al. Tumor suppressor p53 stimulates the expression of Epstein-Barr virus latent membrane protein 1
BR0007690A (pt) Célula recombinante, kit, e, métodos para detectar a presença de vìrus hiv e de diferentes cepas de vìrus hiv em uma amostra, para detectar resistência do hiv à droga em uma amostra, para tomar um paciente que se sabe estar infectado com uma ou mais cepas do vìrus hiv e determinar qual combinação de um ou mais agentes anti-hiv poderia ser efetiva no tratamento do paciente e para triar composições quanto à atividade anti-hiv
El-Mayet et al. Synergistic activation of bovine herpesvirus 1 productive infection and viral regulatory promoters by the progesterone receptor and Krüppel-like transcription factor 15

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]